Navigation Links
Milestone achieved toward production of malaria treatment using synthetic biology and fermentation
Date:2/27/2009

EMERYVILLE, Calif., March 2, 2009 - Amyris Biotechnologies has announced the publication of an article which reveals the achievement of a significant milestone toward the production of amorphadiene, a precursor of the antimalarial agent artemisinin.

The article, "High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli" appears in PLoS ONE, an open-access journal from the Public Library of Science, chronicles the steps taken which enabled Amyris scientists to achieve a crucial milestone in the fight against malaria the production of 25 g/L of amorphadiene through E. coli fermentations.

The production of amorphadiene in E. coli was first described in 2003 but the amount produced was low (50 mg/L). This level was increased to 0.5g/L in 2006, but still 50-fold lower than target production levels. This article describes the interplay of industrial fermentation processes and synthetic biology that achieved the required 50-fold increase in production levels. This milestone acts as proof of concept that commercially relevant concentrations of artemisinin precursors can be produced by microbes for conversion to artemisinin. Publication in PLoS One ensures the information is available free of charge to all nations.

The paper can be found at http://dx.plos.org/10.1371/journal.pone.0004489.

The World Health Organization recommends artemisinin-based combination therapies (ACTs) as first-line treatment for malaria. However, supplies of plant-derived artemisinin are subject to the seasonality and volatility common to many plant-based commodities, leading to fluctuations in the price of artemisinin. Commercial scale production of semi-synthetic artemisinin would have the potential to stabilize supply and supplement existing plant-derived materials to create a consistent, high-quality and
'/>"/>

Contact: Annika Jensen-Lamka
jensen@amyris.com
510-740-7482
Amyris Biotechnologies
Source:Eurekalert

Page: 1 2

Related biology news :

1. A new milestone in the GMES Space Component Program successfully achieved
2. Secure Services Corp. Achieves Milestone in United States Identity Protection with the Launch of the SSC SHAPE Card Management Solution
3. A gentle touch for better control, a quantum mechanical con, and milestone PRL papers
4. Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen
5. Bursts of waves drive immune system soldiers toward invaders
6. MIT works toward safer gene therapy
7. A step toward tissue-engineered heart structures for children
8. Research points towards early cancer detection
9. Researchers take first steps towards spinal cord reconstruction following injury
10. Fish farms drive wild salmon populations toward extinction
11. MIT works toward engineered blood vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... 28, 2008--As atmospheric CO2 levels rise, methods to mitigate ... in the July-August 2008 issue of Soil Science ... of soils as a C sink in different regions ... Rural Development (Canada), the National Institute of Agricultural Technology, ...
... researchers have developed a new technology that promises ... readily available non-food crops, such as Bermudagrass, switchgrass, ... ethanol from renewable biomass sources such as grasses ... large quantities," said Joy Peterson, professor of microbiology ...
... Strange things are happening in the lowland tropical forests ... fly is affecting the social behavior of a nocturnal ... which become workers. The finding by researchers from ... Institute is the first documented example of a parasite ...
Cached Biology News:Soil's carbon storage capacity investigated 2Soil's carbon storage capacity investigated 3New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 2New UGA biomass technology dramatically increases ethanol yield from grasses and yard waste 3A bee's future as queen or worker may rest with parasitic fly 2
(Date:5/21/2015)... (PRWEB) May 21, 2015 Specialty ... audit and been admitted to BPA Worldwide as ... Worldwide will track audience data for Specialty Pharmacy ... , “By becoming a member of BPA ... to providing our clients with the most reliable, ...
(Date:5/21/2015)... Calif. , May 21, 2015  The ... Orrin Hatch (R-UT) and Amy Klobuchar ... Extensions Now Accelerating Cures & Treatments, or OPEN ... rare disease patient advocacy organizations, this bipartisan legislation ... and affordable medicines to rare disease patients by ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, Endetec, ... agreement with VWR to distribute TECTA™ B16, an ... 160 years of experience, VWR, a leading global ... production facilities, has cultivated a value proposition delivering ... enable science. Endetec’s TECTA™ B16, combines proven ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... CHARENTON-LE-PONT, France, August 28 , - Hubert ... The Board of Directors of Essilor International today ... alongside Xavier Fontanet,Chief Executive Officer, and Philippe Alfroid, ... Centrale in Lille and holder of an MBA ...
... N.J., Aug. 27 BD (Becton,Dickinson and Company) (NYSE: ... that it would present at the following investor healthcare,conferences:, ... 4, 2008 1:30 p.m. EDT, Morgan Stanley ... 8:00 a.m. EDT, A live webcast of BD,s ...
... of,Directors, meeting today under the chairmanship of Albert Saporta, approved,STALLERGENES, half year consolidated financial statements:, (EUR millions) ... ... % ... ...
Cached Biology Technology:Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 3
... of Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving ... m/z, * Precursor ion selection range: 150 - 4000 m/z, * ... with internal reference, * Dynamic range: 4 orders of magnitude ... ...
Four siRNAs targeting your gene of interest, providing gene silencing with 100% satisfaction guaranteed High knockdown potency , High specificity for minimal off-target effects , Flexible siR...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... combines Harvard Apparatuss best pump mechanism, a well ... of configuration options. A lookup table in the ... all the major manufacturers. A bright, two line ... from across the lab. All models have RS-232 ...
Biology Products: